Cybin Inc. (OTCMKTS:CYBN – Get Rating) – Research analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Cybin in a research note issued on Monday, March 6th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings per share of ($0.25) for the year, up from their previous estimate of ($0.28). The consensus estimate for Cybin’s current full-year earnings is ($0.24) per share.
Several other research analysts have also recently commented on CYBN. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Cybin in a research note on Wednesday, February 15th. Stifel Nicolaus decreased their price target on Cybin from C$3.00 to C$1.50 in a report on Monday, November 21st. Finally, EF Hutton Acquisition Co. I reissued a “buy” rating and issued a $3.00 target price on shares of Cybin in a report on Tuesday, February 14th.
Cybin Price Performance
Hedge Funds Weigh In On Cybin
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CYBN. Virtu Financial LLC lifted its holdings in shares of Cybin by 104.0% in the fourth quarter. Virtu Financial LLC now owns 90,467 shares of the company’s stock valued at $27,000 after purchasing an additional 46,129 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Cybin by 926.4% during the third quarter. Royal Bank of Canada now owns 109,239 shares of the company’s stock worth $52,000 after acquiring an additional 98,596 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Cybin by 370.6% during the first quarter. Jane Street Group LLC now owns 74,631 shares of the company’s stock worth $61,000 after acquiring an additional 58,771 shares in the last quarter. Belpointe Asset Management LLC purchased a new stake in shares of Cybin during the fourth quarter worth $77,000. Finally, Cantor Fitzgerald L. P. purchased a new stake in shares of Cybin during the third quarter worth $145,000. 9.43% of the stock is owned by institutional investors.
Cybin Company Profile
Cybin, Inc is an ethical biopharmaceutical company engaged in the development of therapeutics for patients to address a multitude of mental health issues. It is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for mental health disorders.
- Get a free copy of the StockNews.com research report on Cybin (CYBN)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ’s Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.